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Abstract
Renal disorders are an emerging problem in HIV-infected patients. We performed a cross-sectional study of the
first 1000 HIV-infected patients attended at our HIV unit who agreed to participate. We determined the fre-
quency of renal alterations and its related risk factors. Summary statistics and logistic regression were applied.
The study sample comprised 970 patients with complete data. Most were white (94%) and men (76%). Median
(IQR) age was 48 (42–53) years. Hypertension was diagnosed in 19%, dyslipidemia in 27%, and diabetes
mellitus in 3%. According to the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation, 29
patients (3%) had an eGFR< 60ml/min/1.73m2; 18 of them (62%) presented altered albumin/creatinine and
protein/creatinine (UPC or UAC) ratios. Of the patients with eGFR> 60mL/min, it was present in 293 (30%), 38
of whom (7.1%) had UPC> 300mg/g. Increased risk of renal abnormalities was correlated with hypertension
(OR, 1.821 [95%CI, 1.292;2.564]; p= 0.001), age (OR, 1.015 [95%CI, 1.001;1.030], per one year; p= 0.040), and
use of tenofovir disoproxil fumarate (TDF) plus protease inhibitor (PI), (OR, 1.401 [95%CI, 1.078;1.821];
p= 0.012). Current CD4 cell count was a protective factor (OR, 0.9995 [95%CI, 0.9991;0.9999], per one cell;
p= 0.035). A considerable proportion of patients presented altered UPC or UAC ratios, despite having an
eGFR> 60mL/min. CD4 cell count was a protective factor; age, hypertension, and use of TDF plus PIs were risk
factors for renal abnormalities. Based on our results, screen of renal abnormalities should be considered in all
HIV-infected patients to detect these alterations early.
Introduction
Astrong association between chronic kidney disease[defined as estimated glomerular filtration rate (eGFR)
<60mL/min/1.73m3] and increased risk of cardiovascular
events and mortality has been reported in the general popula-
tion.1,2 With respect to renal damage, defined as altered albu-
minuria or proteinuria, or other signs of altered urine markers,
are related with an increase in distinct co-morbidities. Specifi-
cally microalbuminuria, macroalbuminuria, or proteinuria, in-
crease both the risk of cardiovascular disease (two- to fourfold)3
and the risk of mortality, independently of renal function, hy-
pertension, or diabetes.4–6 Consequently, it is important to detect
renal damage in early stages.
Regarding theHIV-infected population, the chronic and end-
stage kidney diseases have diminished due to the improvement
of immunological status, although renal alterations still remain
as a problem.7,8 Renal chronic disease is three times more
prevalent than in the general population.9,10 However, the real
frequency of renal abnormalities has been reported to range
from 1% to 30%, depending on the characteristics of the study
population (e.g., race, age, and co-morbidities)11–13 and the
definition of the abnormality evaluated (e.g., chronic kidney
disease or signs of renal damage, that is, presence of protein-
uria, albuminuria, or other signs of altered urine markers) in the
absence of altered estimated glomerular filtration rate (eGFR).
Some of the factors associated with kidney alterations in
HIV-infected patients are common to the general population,
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including, age, arterial hypertension, diabetes, use of poten-
tially nephrotoxic drugs, and hepatitis co-infection; however,
other factors are specific toHIV infection, such as lowCD4 cell
count, highHIV plasma viral load, or use of some antiretroviral
drugs [e.g., tenofovir disoproxil fumarate (TDF)].13–15 As is
usual in several co-morbidities, age is a factor at risk to de-
veloped or worsened renal disease.16
Renal disease has several clinical manifestations, from
subclinical forms of renal damage, to decreased GFR or renal
failure at end stages.11 On the other hand, the relevance of
renal damage in the HIV-infected population can be seen in
the independent association between microalbuminuria and
AIDS-related death (HR, 2.3; 95%CI, 1.3–4.3). Furthermore,
patients with proteinuria are at increased risk for non–AIDS-
related death (HR, 2.4; 95%CI, 1.2–4.6).17,18 Finally, cardio-
vascular events are a frequent cause of non-AIDS mortality in
this population.19
The principal aim of this study was to determine the real
prevalence of kidney abnormalities and related factors in our
setting by assessing a large cohort of HIV-infected patients
attending a tertiary hospital in Spain for routine clinical
control of HIV infection.
Methods
Weperformed a cross-sectional study of the first 1000HIV-
infected outpatients who attended our HIV Unit and agreed to
participate. All the patients signed an informed consent doc-
ument. The study was approved by the Institutional Ethics
Committee of the coordinating center and the local health
authorities. The study period was started at January 2011, and
the last patient was included in December, 2012.
A questionnaire was prospectively completed by all the
patients to obtain data on personal and family history of dia-
betes mellitus, dyslipidemia, hypertension, cardiovascular
events, renal or liver disease, previous or current syphilis, use
of potentially nephrotoxic drugs (e.g., angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, cyclospor-
ine, nonsteroidal anti-inflammatory drugs, and tacrolimus),
physical exercise, and the consumption of tobacco products,
alcohol, and drugs of abuse.
Demographic and HIV-related data were collected from
the patient’s clinical records, as follows: sex, age, risk factors
for HIV infection, clinical stage, time since HIV diagnosis,
time with suppressed viral load, previous and current anti-
retroviral treatment, time on antiretroviral treatment, time on
tenofovir, time on protease inhibitors, and hepatitis co-
infection. Immunologic and virological data were also re-
corded, including current viral load, CD4 and CD8 T-cell
count, peak viral load, and nadir CD4 T-cell count.
Blood and urine samples were collected in fasting condi-
tions. Serum creatinine and phosphate were determined.
Estimated GFR was calculated using theModification of Diet
in Renal Disease equation (MDRD) and the Chronic Kidney
Disease Epidemiology Collaboration (CKD EPI) equations.
Normal local reference values were as follows: eGFR,
> 60mL/min/1.73m2; serum creatinine, < 1.20mg/dL; and
serum phosphate, 2.5–4.50mg/dL. Kidney disease was de-
fined as an eGFR < 60ml/min/1.73m2 and graded according
to the Kidney Disease Outcomes Quality Initiative (KDOQI)
classification.20 Renal damage was defined as the presence of
micro- or macro-albuminuria, or proteinuria, by albumin/
creatinine and protein/creatinine ratios (UACorUPC ratios), or
glucosuria, hematuria, or hipophospatemia. The normal values
for UPC and UAC ratios were < 200 and < 30mg/g, respec-
tively. Subsequently, these ratios was categorized as < 30,
30–300, or > 300mg/g.
Body mass index (BMI) was calculated, and arterial blood
pressure was measured three times with the patient resting.
Arterial hypertension was defined as a systolic blood pressure
of ‡ 140mmHg, diastolic blood pressure of ‡ 90mmHg, or the
need for antihypertensive agents. In case of high readings,
patients were followed up to confirm or rule out the diagnosis of
arterial hypertension. Diabetes was defined as persistent fasting
glycemia > 100mg/dL or the need for antidiabetic agents.
Dyslipidemia was defined as triglycerides > 150mg/dL, total
cholesterol > 200mg/dL, LDL cholesterol > 130mg/dL, or the
need for lipid-lowering drugs.
Statistical analyses
Patient characteristics were described using the mean
(SD), median (IQR), and frequency (%), as appropriate.
Univariate and multivariate logistic regression analyses
were performed to evaluate risk factors that might influence
renal abnormalities (alteration in eGFR or signs of renal
damage).
The predictor variables used in the regression models were
age, smoking, gender, diabetes mellitus, arterial hypertension,
BMI, dyslipidemia, time since diagnosis of HIV, use of poten-
tially nephrotoxic drugs, nadir and current CD4 T-cell count,
months on antiretroviral treatment, type of antiretroviral agent,
use of TDF and of TDF plus protease inhibitors (PIs), time on
protease inhibitors, and time onTDF.Variableswere included in
the multivariate model in such a way as to avoid multicolli-
nearity using a stepwise procedure.
All analyses were performed using SPSS version 15.0
(SPSS Inc., Chicago, IL, USA). All tests were two-sided, and
p values < 0.05 were considered statistically significant.
Results
We offered to participate in the study to all the patients
visited in our AIDS Care Unit. A total of 37 subjects refused
to participate. The main reason to refuse was they did not
have enough time to complete the survey. We recruited the
first 1000 patients who attended the HIV Unit and accepted to
participate. Of these, 30 were subsequently excluded from the
analysis because of missing data. Most of the remaining 970
patients were white (94%) and men (76%), with a median
(IQR) age of 48 (42–53) years. A history of arterial hyper-
tension was self-reported by 9% (in the questionnaire), but
was diagnosed in 19% of patients by means of repetitive
measurements and subsequent clinical evaluation. Dyslipi-
demia was diagnosed in 27% and diabetes mellitus in 3%.
Treatment with antihypertensive agents was taken by 87 pa-
tients (9%), lipid-lowering agents by 142 (4.3%), and hypo-
glycemic agents by 26 (2.7%) (Table 1).
Estimated glomerular filtration rate and classification
according to KDIGO criteria
The median (IQR) eGFR according to the CKD EPI
equation was 101 (89.5; 108.2) mL/min per 1.73m2.
According to the 2012KDIGO criteria, CKDparameters were
normal in 507 patients (52.3%) (eGFR>90mL/min/1.73m2
PREVALENCE OF RENAL DAMAGE IN HIV-INFECTED PATIENTS 525
with no signs of renal damage). Stage 1CKDwas recorded in 213
patients (22%, eGFR>90mL/min/1.73m2 with signs of renal
damage), stage 2 in 221 patients (22.8%, eGFR>60–90mL/min/
1.73m2), and stage 3 in 27 patients (2.8%, eGFR<60mL/min/
1.73m2). One patient (0.1%) had stage 4 CKD (eGFR between
15–30mL/min/1.73m2), and 1 patient (0.1%) had stage 5 disease
(eGFR<15mL/min/1.73m2) (Fig. 1).
Data were very similar for the MDRD equation: 39 patients
(4%) had an eGFR< 60mL/min/1.73m2, 1 patient (0.1%) had
< 15mL/min/1.73m2, 1 patient (0.1%) had 15–30mL/min/
1.73m2, and 37 patients (2.8%) had 30–60mL/min/1.73m2.
Signs of renal damage according to eGFR
Overall, signs of renal damage (abnormal UPC, UAC,
hypophosphatemia, glucosuria, hematuria, or all), was pres-
ent in 311 of the patients (32%). With regard to the eGFR, of
the 29 patients with eGFR (CKD-EPI) < 60mL/min/1.73m2,
Table 1. Patient Characteristics, Overall and According to Grade of Altered Proteinuria
Overall
population
UAC ratio
> 30mg/ga
UPC ratio
> 200mg/ga
UAC or/and
UPC ratios
> 300mg/ga
N = 970 N = 58 N = 75 N = 38
Gender (male), % 733 (75.6%) 58 (100%) 57 (76%) 29 (76.3%)
Ethnicity (white), n (%) 916 (94.4%) 58 (100%) 70 (93.3%) 36 (94.7%)
Age, years 48 (42;53) 44 (40;48) 47.75 (42;53) 51 (47;58.25)
BMI, kg/m2 23.8 (21.7;25.86) 24.24 (23.18;26.04) 23.81 (21.72;25.91) 23.29 (20.71;26.16)
Diabetes, n (%) 35 (3.6%) 0 2 (2.6%) 5 (13%)
Hypertension, n (%) 189 (19.5%) 8 (14%) 14 (18.7%) 16 (42%)
Dyslipidemia 262 (27%) 8 (14%) 20 (26.6%) 12 (31.6%)
Smoking, n (%) 494 (51%) 41 (71%) 38 (50.6%) 12 (31.5%)
Hepatitis B/C co-infection,
n (%)
270 (27.5%) 33 (57%) 20 (26.7%) 13 (34%)
Potentially nephrotoxic
concomitant therapy, n (%)
115 (12%) 0 9 (12%) 8 (21%)
Time since diagnosis
of HIV infection, years
14.95 (7.43;19.74) 9.51 (5.28;18.58) 14.87 (7.318;19.56) 16.95 (13.23;22.47)
Current CD4 + T-cell count,
cells/lL
567 (402;766.25) 577 (337;708) 576 (416;771) 487.5 (290;577.5)
Nadir CD4 + T-cell count,
cells/lL
214.5 (99;326) 274 (91;319) 219 (103;327) 136.5 (88.25;254)
Suppressed viral load, n (%) 811 (83.6%) 66 (85.7%) 63 (84%) 32 (84.2%)
Time on ARV treatment,
months
151.3 (70.78;192.3) 90.31 (13.28;135.45) 151.39 (71.11;190.68) 168.25 (134.05;211.34)
Current use of PI, n (%) 499 (51.4%) 58 (100%) 60 (80%) 34 (89.4%)
Time on PI, months 70.85 (31.41;124.8) 43.56 (13.28;48) 71.54 (32.35;125.72) 80.97 (25.75;144.69)
Current use of TDF, n (%) 491 (50.6%) 19 (43%) 34 (45%) 20 (52.6%)
Time on TDF, months 32.75 (17.63;49.71) 23.60 (19.56;38.46) 32.81 (17.88;49.81) 30.51 (14.59;42.97)
ARV, antiretroviral; BMI, body mass index; IQR, interquartile range; n, number of patients; PI, protease inhibitors; TDF, tenofovir; UAC
ratio, urine albumin creatinine ratio; UPC ratio, urine protein creatinine ratio. Data are expressed as the median (IQR) unless otherwise indicated.
aGrade of UAC or UPC are irrespective to the e GFR.
FIG. 1. Flow chart. eGFR: estimated glomerular filtration rate; kidney damage: altered albumin/creatinine and protein/creatinine
ratios (UPC or UAC ratios), or presence of glucosuria, hematuria or hipophospatemia; UPC or UAC ratios: urinary proteinuria/
creatinine or albuminuria/creatinine ratios.
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18 (62%) presented any sign of renal damage. Of those with
eGFR > 60mL/min/1.73m2, renal damage was present in 297
(30%). Indeed in the case of a normal function (eGFR > 90
mL/min/1.73m2), signs of renal damage are present in 213
patients from 720 (29.6%). Specifically, abnormal UPC or
UAC ratios (UPC > 200mg/g and/or UAC > 30mg/g) was
detected in 75 (7.8%) and 58 (6%) patients, respectively.
Considering only those patients with abnormal UPC or
UAC ratios, median values for the albumin/creatinine and
protein/creatinine ratios were 54.8 (38.7;91.05) mg/g and 309
(246;470) mg/g, respectively.
Seventy seven patients (8%) had UAC ratio < 30 (median
[IQR], 0.9 [0.07;10]) mg/g, and 38 patients (4%) had UPC or
UAC ratios > 300 (467 [351;887.75]) mg/g.
Related factors
Logistic regression was performed in two cases: altered
eGFR and/or abnormal UPC or UAC ratios and normal eGFR
and in case of proteinuria > 300mg/g. The results from the
univariate and multivariate analyses are summarized in
Table 2.
Multivariate regression from the first model showed as-
sociations between an increased risk of abnormal UPC or
UAC ratios and: hypertension [OR 1.821, (95%IC: 1.292;
2.564), p = 0.001], age [per 1 year, OR 1.015, (95%IC
1.001;1.030), p = 0.040], BMI bellow 18 or above 30 kg/m2
[OR 2.1277, (95%IC:1.335; 3.39), p = 0.001] and use of TDF
plus PI, [OR 1.401, (95%IC:1.078;1.8215), p = 0.012)]. Cur-
rent CD4 cells count [per one cell of increase, OR 0.9995,
(95%IC 0.9991;0.9999), p= 0.035] was a protector factor.
In the multivariate analysis of the second model, the only
variables associated with proteinuria > 300mg/g were diabetes
mellitus ( p= 0.018) and arterial hypertension ( p= 0.007).
Logistic regression analysis based on the MDRD equation
revealed similar risk factors to the analysis based on the
CKD-EPI equation (data not shown).
Discussion
The main findings of our cross-sectional study were a low
percentage of patients with renal disease (eGFR < 60mL/
min/1.73m2) but, importantly, the high prevalence of signs of
kidney damage, in patients with an eGFR > 60mL/min/
1.73m2 and even with normal eGFR ( > 90mL/min/1.73m2).
This finding has important clinical implications for the
management and control of the HIV population and led these
patients as an at risk population. In addition, we also detected
that arterial hypertension was an underdiagnosed risk factor
in our cohort.
Consistent with findings of other HIV-infected populations
in the same geographical area, advanced renal disease was
infrequent in our study (0.2%). Results from European co-
horts show a prevalence of kidney disease (eGFR < 60mL/
min/1.73m2) to be 2–5%.21–23 The relatively low median age
(48 years) of our patients likely explains this finding. How-
ever, the high prevalence of patients with signs of renal
damage, most of whom had an eGFR > 60mL/min/1.73m2 is
similar to other results recently reported elsewhere,21 and,
contrary, is lower than others regarding the proportion of
proteinuria detected.23 Interestingly, these others signs of
renal damage (no only AUC or UPC altered) could appear
earlier than proteinuria in the case of renal alteration, and this
is a possible explanation of the differences in the results re-
garding the distinct parameters evaluated. it should be take in
consideration in order to early detect and manage this alter-
ations, even when a normal eGFR is present.
Table 2. Logistic Regression Model
Univariate Multivariate
Odds ratio [95%CI] p Value Odds ratio [95%CI] p Value
First model. Factors related with altered eGFR and/or abnormal UPC or UAC
Age (per 1 year of increase) 1.017 [1.00343;1.03082] 0.014 1.015 [1.001;1.030] 0.040
Hypertension (yes vs. no) 1.852 [1.337; 2.564] < 0.001 1.821 [1.292;2.564] 0.001
Hepatitis coinfection (yes vs. no) 1.414 [1.066098;1.876173] 0.016
BMI < 18.5 or > 30 kg/m2 (yes vs. no) 2.169 [1.373626;3.436426] 0.001 2.1277 [1.335;3.39] 0.001
Current TDF use (yes vs. no) 1.348 [1.04603;1.7331] 0.021
Use of NRTIs (yes vs. no) 1.335 [1.030928;1.730104] 0.028
Use of TDF plus PIs (yes vs. no) 1.335 [1.037344;1.718213] 0.025 1.401 [1.078;1.8215] 0.012
Current CD4 cell count
(per increase of one cell)
0.99945 [0.999016;0.99989] 0.014 0.9995 [0.9991;0.9999] 0.035
Exercise (1 or more hours per week) 0.6238 [0.48403;0.80386] < 0.001
Second model. Factors related to proteinuria > 300mg/g
Age (per 1 year of increase) 1.060 [1.021;1.101] 0.002
Hypertension (yes vs. no) 3.236 [1.516;6.924] 0.002 2.91 [1.339;6.329] 0.007
Diabetes mellitus (yes vs. no) 5.242 [1.697;16.194] 0.004 4.051 [1.270;12.919] 0.018
Time on antiretroviral treatment
(per 1 year)
1.0002469 [1.0000538;1.0004399] 0.012
Nadir CD4 cell count
(per increase of one cell)
0.997 [0.994;0.9996] 0.027
Current use of Darunavir 3.404 [1.021;11.351] 0.046
BMI, body mass index; eGFR, estimated glomerular filtration rate; PI, protease inhibitor; NRTIs, nucleoside reverse transcriptase
inhibitors; TDF, tenofovir; UPC, urine protein/creatinine ratio; UAC, urine albumin/creatinine ratio.
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The relevance of abnormal UPC or UAC ratios is strongly
associated with cardiovascular events and death in the gen-
eral population, irrespective of the grade of albuminuria or
proteinuria.5 A recent meta-analysis of more than 170,000
patients from 26 cohort studies concluded that patients with
abnormal UPC or UAC ratios (even those with < 30mg/g)
have a ‡ 50% greater risk of coronary heart disease than
those without proteinuria.3 In the HIV-infected population,
recently published articles report a correlation between mi-
croalbuminuria/proteinuria and a two-fold increased risk of
both AIDS- and non–AIDS-related mortality.18,24 Conse-
quently, HIV-infected patients should be considered a risk
population and renal damage should be assessed, even in
patients without other risk factors (e.g., age > 60 years, ar-
terial hypertension, and diabetes mellitus).25
Also relevant is the considerable number of new diagnoses
of arterial hypertension in our patients. Given that hypertension
is a well-established risk factor for renal damage, blood pres-
sure should be assessed routinely in the HIV-infected popula-
tion. Metabolic abnormalities such as diabetes mellitus,
dyslipidemia, and arterial hypertension are progressively more
frequent, and clinical monitoring of these risk factors is in-
creasingly relevant.
Many of the factors associated with altered eGFR and
proteinuria were common to those observed in the general
population (such as extreme BMI or older age), supporting
data from previous studies.26,27 We expect an increase of
renal disturbances in the next future among HIV-infected
people due to their improvement of life expectancy. In fact,
aging is related not only with an increased incidence of
renal disease but also with an increased incidence of other co-
morbidities.16
However, in contrast with findings reported elsewhere,13–15
viral load was not associated with an increase in the risk of
kidney disease or proteinuria in our study, probably because
of the viral suppression and preserved immune status (a
protective factor) recorded in the most of our patients, which
reduced the impact of HIV-related factors on renal alter-
ations.
Tenofovir has been associated with tubular injury,28 and
proximal renal tubulopathy is the most common histopa-
thology finding;29 in contrast, altered GFR and advanced
renal disease due to tenofovir seem to be infrequent.30,31 Our
data showed that the use of tenofovir combined with a pro-
tease inhibitor increased the risk of kidney disease (abnormal
eGFR and abnormal UPC or UAC ratios), as previously de-
scribed in large cohorts.15,22,32 Higher tenofovir plasma
concentration was associated with alterations in renal mark-
ers (both glomerular and tubular),33,34 and the highest plasma
exposure was associated with the concomitant use of protease
inhibitors.35 However, whether co-administered or not with
protease inhibitors, tenofovir was not associated with pro-
teinuria > 300mg/g in our cohort. In fact, the most common
form of TDF-related toxicity is a low level of proteinuria,27
that is usually reversible after the interruption of the drug.36
Our study has several limitations. First, its cross-sectional
design could lead us to overestimate the prevalence of renal
abnormalities, because of only one determination of blood
and urine was collected. Second, the cross-sectional design is
unable to evaluate the evolution of the renal alterations de-
tected. Finally, since we included mainly white men, our
results cannot be extrapolated to other populations. Never-
theless, our study provides a reasonable picture of renal
damage in the HIV-infected population in our setting.
In conclusion, severe kidney disease (eGFR < 60mL/min/
1.73m2) was infrequent in our cohort; in contrast, signs of
renal damage (mostly altered UPC or UAC ratios) were
highly frequent, despite a normal eGFR. These data highlight
the susceptibility of this population, and the need for early
detection of renal injury, even in patients with normal renal
function. In addition to HIV-related factors, factors common
to the general population (e.g., age, arterial hypertension,
diabetes, and extreme BMI) emerge as potentially major risk
factors of renal damage.
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